NO20061876L - Optimalisert uttrykking av HPV45-L1 i gjaer - Google Patents
Optimalisert uttrykking av HPV45-L1 i gjaerInfo
- Publication number
- NO20061876L NO20061876L NO20061876A NO20061876A NO20061876L NO 20061876 L NO20061876 L NO 20061876L NO 20061876 A NO20061876 A NO 20061876A NO 20061876 A NO20061876 A NO 20061876A NO 20061876 L NO20061876 L NO 20061876L
- Authority
- NO
- Norway
- Prior art keywords
- hpv45
- protein
- vlps
- vaccines
- prepare
- Prior art date
Links
- 241000985694 Polypodiopsida Species 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 108020004705 Codon Proteins 0.000 abstract 1
- 208000009608 Papillomavirus Infections Diseases 0.000 abstract 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 210000005253 yeast cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50681203P | 2003-09-29 | 2003-09-29 | |
PCT/US2004/031326 WO2005032586A1 (en) | 2003-09-29 | 2004-09-24 | Optimized expression of hpv 45 l1 in yeast |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20061876L true NO20061876L (no) | 2006-04-28 |
NO339932B1 NO339932B1 (no) | 2017-02-20 |
Family
ID=34421558
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20061876A NO339932B1 (no) | 2003-09-29 | 2006-04-28 | Nukleinsyremolekyl som koder for et HPV45-L1-protein, vektor som omfatter nukleinsyremolekylet, vertscelle som omfatter vektoren, samt en fremgangsmåte for fremstilling av HPV45-L1-viruslignende partikler (VLPer) i gjær og en fremgangsmåte for å fremstille en vaksine for behandling eller forebygging av HPV infeksjoner. |
NO2017012C NO2017012I1 (no) | 2003-09-29 | 2017-04-05 | HPV 45 L1 protein |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2017012C NO2017012I1 (no) | 2003-09-29 | 2017-04-05 | HPV 45 L1 protein |
Country Status (33)
Country | Link |
---|---|
US (2) | US7250170B2 (no) |
EP (1) | EP1673106B1 (no) |
JP (4) | JP5451960B2 (no) |
KR (1) | KR101165278B1 (no) |
CN (1) | CN1859923B (no) |
AR (2) | AR045804A1 (no) |
AT (1) | ATE435029T1 (no) |
AU (1) | AU2004277934B2 (no) |
BE (1) | BE2015C072I2 (no) |
BR (1) | BRPI0414845B8 (no) |
CA (1) | CA2539168C (no) |
CY (2) | CY1110525T1 (no) |
DE (1) | DE602004021828D1 (no) |
DK (1) | DK1673106T3 (no) |
ES (1) | ES2327530T3 (no) |
FR (1) | FR15C0083I2 (no) |
HU (1) | HUS1500063I1 (no) |
IL (1) | IL174458A (no) |
IS (1) | IS2694B (no) |
LT (2) | LTC1673106I2 (no) |
LU (1) | LU92902I2 (no) |
MX (1) | MXPA06003457A (no) |
MY (1) | MY140664A (no) |
NL (1) | NL300776I2 (no) |
NO (2) | NO339932B1 (no) |
NZ (1) | NZ545834A (no) |
PL (1) | PL1673106T3 (no) |
PT (1) | PT1673106E (no) |
RU (1) | RU2360001C2 (no) |
SI (1) | SI1673106T1 (no) |
TW (1) | TWI350853B (no) |
WO (1) | WO2005032586A1 (no) |
ZA (1) | ZA200601961B (no) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
US7858098B2 (en) * | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
MY139500A (en) | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
TWI349036B (en) | 2004-03-24 | 2011-09-21 | Merck Sharp & Dohme | Optimized expression of hpv 52 l1 in yeast |
US7758866B2 (en) | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
CA2604909A1 (en) | 2005-04-15 | 2006-10-26 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
SG159525A1 (en) * | 2005-04-26 | 2010-03-30 | Glaxosmithkline Biolog Sa | Vaccine |
US8101342B2 (en) * | 2006-08-28 | 2012-01-24 | Sungkyunkwan University Foundation For Corporate Collaboration | DNA vaccine for treating or preventing cervical cancer comprising a gene encoding HPV protein |
JP2010520874A (ja) * | 2007-03-09 | 2010-06-17 | メルク・シャープ・エンド・ドーム・コーポレイション | パピローマウイルスワクチン組成物 |
EP2479187A1 (en) * | 2007-11-23 | 2012-07-25 | Shanghai Zerun Biotechnology Co., Ltd. | Genes encoding major capsid protein L1 of human papilloma viruses |
PL2444103T3 (pl) | 2009-06-19 | 2018-05-30 | Eyegene Inc. | Szczepionka przeciwko rakowi szyjki macicy |
CA2799205A1 (en) | 2010-05-25 | 2011-12-01 | Qiagen Gaithersburg, Inc. | Fast results hybrid capture assay and associated strategically-truncated probes |
CN103717741B (zh) * | 2011-06-15 | 2016-04-13 | 中央大学校产学协力团 | 用于提高人乳头瘤病毒l1蛋白产量的方法 |
WO2012177970A1 (en) | 2011-06-24 | 2012-12-27 | Merck Sharp & Dohme Corp. | Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same |
CN103215302B (zh) * | 2012-01-21 | 2019-01-15 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv18 l1蛋白的方法 |
CN108624614A (zh) * | 2012-03-28 | 2018-10-09 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv11 l1蛋白的方法 |
CN104120088B (zh) * | 2013-04-26 | 2019-09-24 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv58 l1蛋白的方法 |
CN104120089B (zh) * | 2013-04-26 | 2019-09-24 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv52 l1蛋白的方法 |
CN104164447B (zh) * | 2013-05-17 | 2019-08-13 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv45 l1蛋白的方法 |
CN112280792B (zh) * | 2013-09-29 | 2022-06-24 | 上海泽润生物科技有限公司 | 人乳头瘤病毒基因,及载体,菌株,表达方法 |
US9782470B2 (en) | 2013-10-16 | 2017-10-10 | Merck Sharp & Dohme Corp. | Method of obtaining thermostable dried vaccine formulations |
BR112017004181A2 (pt) * | 2014-09-11 | 2017-12-05 | Cadila Healthcare Ltd | ?gene, vetor, célula hospedeira, partículas similares a vírus, vacina para vírus de papiloma humano, composição imunogênica, adjuvante, método para o preparo de uma vacina de papiloma humano, proteína de capsídeo principal e proteína hpv l1? |
CN106282278B (zh) * | 2015-06-29 | 2021-06-08 | 广东东阳光药业有限公司 | 一种人乳头瘤病毒l1蛋白的发酵方法 |
CN106701798B (zh) * | 2015-08-12 | 2021-09-17 | 北京康乐卫士生物技术股份有限公司 | 45型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN109750050B (zh) * | 2017-11-07 | 2023-08-18 | 上海泽润生物科技有限公司 | 重组人乳头瘤病毒45亚型蛋白表达 |
AU2021219652A1 (en) | 2020-02-14 | 2022-08-18 | Merck Sharp & Dohme Llc | HPV vaccine |
CN112680462B (zh) * | 2020-12-29 | 2022-02-22 | 上海博唯生物科技有限公司 | 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用 |
CN113073105B (zh) * | 2021-03-23 | 2023-06-13 | 重庆博唯佰泰生物制药有限公司 | 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用 |
TW202313658A (zh) | 2021-08-06 | 2023-04-01 | 美商默沙東有限責任公司 | Hpv疫苗 |
EP4387660A1 (en) | 2021-08-19 | 2024-06-26 | Merck Sharp & Dohme LLC | Thermostable lipid nanoparticle and methods of use thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA96005662A (es) * | 1994-05-16 | 2004-08-19 | Merck & Co Inc | Vacunas de papilomavirus. |
AR004464A1 (es) * | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
IL117459A (en) * | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
IL117591A0 (en) * | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
ATE342916T1 (de) | 1997-02-07 | 2006-11-15 | Merck & Co Inc | Synthetische hiv gag gene |
WO1998054339A1 (en) * | 1997-05-27 | 1998-12-03 | Hanil Synthetic Fiber Co., Ltd. | PROCESS FOR PREPARING RECOMBINANT PROTEINS USING HIGHLY EFFICIENT EXPRESSION VECTOR FROM $i(SACCHAROMYCES CEREVISIAE) |
CA2296067C (en) | 1997-07-09 | 2008-10-07 | The University Of Queensland | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
US6991795B1 (en) * | 1998-08-14 | 2006-01-31 | Merck & Co., Inc. | Protein delivery system using human papillomavirus virus-like particles |
EP1105157B1 (en) * | 1998-08-14 | 2006-11-02 | Merck & Co., Inc. | Protein delivery system using human papillomavirus virus-like particles |
JP2002535965A (ja) * | 1998-12-23 | 2002-10-29 | メルク エンド カムパニー インコーポレーテッド | ヒトパピローマウイルス・ウイルス様粒子を使用した中和アッセイ |
WO2001014416A2 (en) * | 1999-08-25 | 2001-03-01 | Merck & Co., Inc. | Synthetic papillomavirus genes optimized for expression in human cells |
US6436402B1 (en) * | 1999-10-15 | 2002-08-20 | Merck & Co., Inc. | Process for making human papillomavirus virus-like particles with improved properties |
US7026443B1 (en) | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
KR100874552B1 (ko) | 2000-07-21 | 2008-12-16 | 글락소 그룹 리미티드 | 코돈-최적화 파필로마 바이러스 서열 |
WO2003068163A2 (en) * | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Optimization of gene sequences of chimeric virus-like particles for expression in insect cells |
GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
AU2004224335B2 (en) | 2003-03-24 | 2010-01-28 | Merck Sharp & Dohme Llc | Optimized expression of HPV 31 L1 in yeast |
-
2004
- 2004-09-21 MY MYPI20043867A patent/MY140664A/en unknown
- 2004-09-22 AR ARP040103420A patent/AR045804A1/es active IP Right Grant
- 2004-09-23 TW TW093128883A patent/TWI350853B/zh active
- 2004-09-24 ES ES04788982T patent/ES2327530T3/es active Active
- 2004-09-24 DK DK04788982T patent/DK1673106T3/da active
- 2004-09-24 WO PCT/US2004/031326 patent/WO2005032586A1/en active Application Filing
- 2004-09-24 NZ NZ545834A patent/NZ545834A/en active IP Right Revival
- 2004-09-24 CN CN2004800281067A patent/CN1859923B/zh active Active
- 2004-09-24 KR KR1020067006044A patent/KR101165278B1/ko active IP Right Grant
- 2004-09-24 AU AU2004277934A patent/AU2004277934B2/en active Active
- 2004-09-24 SI SI200431180T patent/SI1673106T1/sl unknown
- 2004-09-24 AT AT04788982T patent/ATE435029T1/de active
- 2004-09-24 PT PT04788982T patent/PT1673106E/pt unknown
- 2004-09-24 MX MXPA06003457A patent/MXPA06003457A/es active IP Right Grant
- 2004-09-24 US US10/573,330 patent/US7250170B2/en active Active
- 2004-09-24 JP JP2006528190A patent/JP5451960B2/ja active Active
- 2004-09-24 RU RU2006114701/13A patent/RU2360001C2/ru active
- 2004-09-24 CA CA2539168A patent/CA2539168C/en active Active
- 2004-09-24 DE DE602004021828T patent/DE602004021828D1/de active Active
- 2004-09-24 BR BRPI0414845A patent/BRPI0414845B8/pt active IP Right Grant
- 2004-09-24 PL PL04788982T patent/PL1673106T3/pl unknown
- 2004-09-24 EP EP04788982A patent/EP1673106B1/en active Active
-
2006
- 2006-03-08 ZA ZA200601961A patent/ZA200601961B/en unknown
- 2006-03-20 IS IS8362A patent/IS2694B/is unknown
- 2006-03-21 IL IL174458A patent/IL174458A/en active IP Right Grant
- 2006-04-28 NO NO20061876A patent/NO339932B1/no active Protection Beyond IP Right Term
-
2007
- 2007-05-23 US US11/805,453 patent/US7482015B2/en active Active
-
2009
- 2009-09-21 CY CY20091100973T patent/CY1110525T1/el unknown
-
2010
- 2010-07-07 AR ARP100102440A patent/AR077396A2/es not_active Application Discontinuation
-
2011
- 2011-03-02 JP JP2011045589A patent/JP2011152137A/ja active Pending
-
2014
- 2014-06-24 JP JP2014129350A patent/JP2014221052A/ja active Pending
-
2015
- 2015-11-30 NL NL300776C patent/NL300776I2/nl unknown
- 2015-12-02 HU HUS1500063C patent/HUS1500063I1/hu unknown
- 2015-12-04 FR FR15C0083C patent/FR15C0083I2/fr active Active
- 2015-12-07 CY CY2015050C patent/CY2015050I1/el unknown
- 2015-12-08 LT LTPA2015049C patent/LTC1673106I2/lt unknown
- 2015-12-08 LT LTPA2015049D patent/LTPA2015049I1/lt unknown
- 2015-12-08 LU LU92902C patent/LU92902I2/xx unknown
- 2015-12-09 BE BE2015C072C patent/BE2015C072I2/nl unknown
-
2016
- 2016-02-04 JP JP2016019712A patent/JP2016136947A/ja active Pending
-
2017
- 2017-04-05 NO NO2017012C patent/NO2017012I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20061876L (no) | Optimalisert uttrykking av HPV45-L1 i gjaer | |
NO20062674L (no) | Optimalisert uttrykking av HPV58-L1 i gjaer | |
NO2018010I1 (no) | HPV 31 L1 protein | |
NO20064815L (no) | Optimalisert uttrykking av HPV 52-L1 i gjaer | |
WO2007066334A9 (en) | Improved influenza vaccine | |
IL164812A0 (en) | Packaged virus-like particles for use as adjuvants: method of preparation and use | |
WO2004084939A8 (en) | Hiv-peptide-carrier-conjugates | |
WO2001014416A3 (en) | Synthetic papillomavirus genes optimized for expression in human cells | |
TW200607858A (en) | Optimized expression of HPV 31 L1 in yeast | |
WO2005034841A3 (en) | Anthrax vaccine | |
MY138895A (en) | Optimized expression of hpv 31 l1 in yeast | |
TH108752B (th) | การแสดงที่ถูกทำให้เหมาะสมที่สุดของ hpv 52 l1 ในยีสต์ | |
WO2006114273A3 (en) | Vaccine | |
TW200716169A (en) | Vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: HPV 45 L1 PROTEIN; NAT. REG. NO/DATE: EU/1/15/1007/001-3 20150610; FIRST REG. NO/DATE: EU/1/15/1007/1001-3 20150610 Spc suppl protection certif: 2017012 Filing date: 20170405 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: HPV 45 L1 PROTEIN; NAT. REG. NO/DATE: EU/1/15/1007/001-3 20150610; FIRST REG. NO/DATE: EU/1/15/1007/1001-3 20150612 Spc suppl protection certif: 2017012 Filing date: 20170405 Extension date: 20290924 |
|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MERCK SHARP & DOHME LLC, US |
|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: HPV 45L1 PROTEIN - FORLENGELSE SPC; REG. NO/DATE: EU/1/15/1007/001-3 20150610 Spc suppl protection certif: 2022051 Filing date: 20221130 |